Boone Capital Management LLC Buys New Shares in uniQure N.V. $QURE

Boone Capital Management LLC bought a new position in shares of uniQure N.V. (NASDAQ:QURE) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 147,317 shares of the biotechnology company’s stock, valued at approximately $8,599,000. uniQure makes up about 2.8% of Boone Capital Management LLC’s holdings, making the stock its 14th largest holding.

Several other hedge funds have also recently added to or reduced their stakes in QURE. Algert Global LLC boosted its stake in shares of uniQure by 17.9% during the 3rd quarter. Algert Global LLC now owns 22,810 shares of the biotechnology company’s stock worth $1,331,000 after acquiring an additional 3,470 shares in the last quarter. Apis Capital Advisors LLC acquired a new position in shares of uniQure in the 3rd quarter worth $3,724,000. Creative Planning acquired a new stake in shares of uniQure during the third quarter worth $276,000. Schonfeld Strategic Advisors LLC raised its position in shares of uniQure by 39.5% during the third quarter. Schonfeld Strategic Advisors LLC now owns 188,197 shares of the biotechnology company’s stock worth $10,985,000 after purchasing an additional 53,249 shares during the period. Finally, Virtu Financial LLC lifted its holdings in shares of uniQure by 42.1% during the third quarter. Virtu Financial LLC now owns 28,201 shares of the biotechnology company’s stock valued at $1,646,000 after purchasing an additional 8,351 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and maintained a $70 price target on QURE, giving some institutional-support context despite lowered estimates. HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE)
• Neutral Sentiment: Market/opinion coverage is running — e.g., a Seeking Alpha piece frames uniQure’s situation as complex and worth reading for background, but it does not add new regulatory facts. A Unique Situation For UniQure
• Negative Sentiment: FDA reportedly issued an unprecedented public rebuke alleging uniQure pushed “distorted” or “manipulated” data related to AMT‑130; plaintiffs’ firms are citing that as the basis to expand securities investigations — a major regulatory risk for the company’s lead program and valuation. QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data …
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs in securities class actions (class period: Sept. 24–Oct. 31, 2025) and have set an April 13, 2026 lead‑plaintiff filing deadline — increasing legal and settlement-tail risk. Representative filings/alerts include Kessler Topaz, Pomerantz and Schall. uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz … QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit …
• Negative Sentiment: HC Wainwright materially cut near‑ and long‑term EPS forecasts (Q1–Q4 2026 and FY2026–FY2030), reducing future earnings visibility and implying a slower timeline to commercialization/profitability despite the Buy rating. That revision increases downside risk to current valuation. uniQure (NASDAQ: QURE) analyst/estimate coverage — MarketBeat

uniQure Stock Performance

Shares of QURE stock opened at $15.53 on Friday. The company has a market capitalization of $971.09 million, a price-to-earnings ratio of -4.50 and a beta of 0.73. uniQure N.V. has a 1-year low of $7.76 and a 1-year high of $71.50. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. The stock’s fifty day simple moving average is $21.37 and its 200-day simple moving average is $29.59.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. On average, sell-side analysts predict that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares in the company, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $30,912.72. Following the transaction, the insider directly owned 138,483 shares in the company, valued at $1,254,655.98. The trade was a 2.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 81,399 shares of company stock worth $1,527,645 over the last ninety days. 4.79% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Chardan Capital increased their price target on uniQure from $16.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, March 9th. TD Cowen restated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Leerink Partners reaffirmed an “outperform” rating and set a $35.00 price objective on shares of uniQure in a research note on Monday, March 2nd. Stifel Nicolaus set a $14.00 target price on shares of uniQure in a report on Monday, March 2nd. Finally, Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, uniQure presently has an average rating of “Moderate Buy” and an average price target of $43.25.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.